Beyond the Benchmark by EFG · 2024-03-14 · 39 min
In the world of Healthcare, few recent innovations have caused as much of a stir as the emergent GLP-1 agonist drugs, which have proven to have a material impact on weight loss. In this episode Moz is joined by New Capital's Mike Clulow and Chelsea Wiater to talk through what GLP-1s are, how they work and the potentially far reaching impacts they may have on the consumer staples and healthcare industries. Our host, Moz Afzal: Our guests: Mike Clulow, Senior Portfolio Manager, New Capital Chelsea Wiater, Portfolio Manager, New Capital EFGAM: Important disclaimers The value of investments and the income derived from them can fall as well as rise, and past performance is no indicator of future performance. Investment products may be subject to investment risks involving, but not limited to, possible loss of all or part of the principal invested. This document does not constitute and shall not be construed as a prospectus, advertisement, public offering or placement of, nor a recommendation to buy, sell, hold or solicit, any investment, security, other financial instrument or other product or service.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
EP 148: Is the AI boom cracking? Inside July’s sell-off and beyond85 / 100
EP 145: EFG’s Mid-Year Outlook: what to know now and how to act68 / 100
EP 147: Where technology ends and human intuition begins - onboard with Team Malizia
EP 146: Secondaries first: rethinking private market liquidity
EP 144: Strongmen, sanctions and the Strait of Hormuz: Navigating today’s new geopolitical order
